Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Receptor Agonist
100%
High Potency
100%
Glucagon-like
100%
1 Receptor
100%
Glucagon-like peptide-1 Receptor Agonists (GLP-1 RAs)
100%
Weight Loss
46%
Without Diabetes
30%
Commercially Insured
15%
Tirzepatide
15%
Pre-period
15%
Treatment Persistence
15%
Drug Claims
15%
Semaglutide
15%
Clinical Trials
7%
Cost-effectiveness
7%
Clinical Efficacy
7%
Management Program
7%
Dose Escalation
7%
Medication Adherence
7%
Diabetes Diagnosis
7%
Persistence Rate
7%
Ence
7%
Pharmacy Claims Data
7%
Treatment Discontinuation
7%
Medical Claims Data
7%
Proportion of Days Covered
7%
Product Switching
7%
Lifestyle Management
7%
Product Availability
7%
Potential Influencing Factors
7%
Medical Claims
7%
Days of Supply
7%
Side Effect Management
7%
Discontinuation Reasons
7%
Product Scarcity
7%
Wegovy
7%
1-year Persistence Rates
7%
Zepbound
7%
Diabetes Drugs
7%
Pharmacology, Toxicology and Pharmaceutical Science
Tirzepatide
100%
Semaglutide
100%
Glucagon Like Peptide 1 Receptor Agonist
100%
Clinical Trial
50%
Cohort Study
50%
Side Effect
50%
Medicine and Dentistry
Diabetes
100%
Glucagon-Like Peptide-1 Agonist
100%
Semaglutide
33%
Tirzepatide
33%
Health Care Cost
16%
Clinical Trial
16%
Cohort Analysis
16%
Side Effect
16%